spacer
home > ebr > winter 2002 > non-viral gene delivery methods
PUBLICATIONS
European Biopharmaceutical Review

Non-Viral Gene Delivery Methods

The last decade has seen substantial progress in the development and application of non-viral vectors in gene therapy. Infectious disease, genetic defects and even traumatic injury may someday be treated with gene therapy and gene transfer strategies. The potential impact of this new technology on human disease has produced optimism and expectation for scientists and lay people alike. As more effort is directed at developing the potential of this technology, it has become evident that the success or failure of gene therapeutic approaches will centre on the ability to manipulate and control the process of genetic transfer into somatic cells.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Günter Kraus, Vice President of Research and Development at amaxa GmbH Dr Günter Kraus is Vice President of Research and Development at amaxa GmbH, a German biotechnology company based in Cologne. Prior to joining the company in 2002, he spent 12 years at two academic institutions in the USA, where he was a Principal Investigator into DNA-based HIV vaccines, and received a prestigious amfAR award and a Susan G. Komen Foundation breast cancer research award. Günter holds a PhD in Microbiology from the JohannWolfgang-Goethe University, Germany and wrote his thesis on infectious diseases at the Paul-Ehrlich Institute.
He has extensive knowledge of the development of viral and non-viral gene delivery systems and in the field of gene therapy. He has also co-authored numerous research articles in peer reviewed scientific journals and several US-issued patents.

spacer
Dr Günter Kraus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement